Skip to content

Innoviva, Inc. INVA Non-cash interest expense

Non-cash interest expense at other companies

Insmed logo
InsmedINSM
Ligand Pharmaceuticals logo
Ligand PharmaceuticalsLGND
ANI Pharmaceuticals logo
ANI PharmaceuticalsANIP
Option Care Health, Inc. logo
Option Care Health, Inc.OPCH

Other financials

Income statement

See full
Revenue$98.0M+10.6%
Gross profit$75.8M+3.4%
Operating income$38.2M-7.9%
Net income$186.6M+501%
EPS (diluted)$2.22+400%

Balance sheet

See full
Cash & equivalents$603.1M+89.0%
Total debt$269.4M-40.3%
Total equity$1.3B
Total assets$1.8B+46.4%

Cash flow

See full
Operating cash flow$35.3M-27.4%
CapEx$492.0K
Free cash flow$34.8M-28.4%

Valuation

See full
Market cap$1.74B+51.8%
Enterprise value$1.41B+9.7%
P/E3.5×
P/S4.2×+1.0×

Profitability

See full
Gross margin73.7%-9.9pp
Operating margin38.1%-11.2pp
Net margin119.9%+107pp
FCF margin54.1%+5.3pp

Returns & leverage

See full
Return on equity29.1%
Debt / equity0.2×
Current ratio21.1×+18.7×

Where this comes from

Reported directly by Innoviva, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfFinancingCostsAndDiscounts.

The official record: Innoviva, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Innoviva, Inc.'s non-cash interest expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Innoviva, Inc.'s non-cash interest expense?
Innoviva, Inc. (INVA) reported non-cash interest expense of $364K in Q1 2026.
How has Innoviva, Inc.'s non-cash interest expense changed year-over-year?
Innoviva, Inc.'s non-cash interest expense decreased by 32.7% year-over-year, from $541K to $364K.
What is the long-term trend for Innoviva, Inc.'s non-cash interest expense?
Over 4 years (2021 to 2025), Innoviva, Inc.'s non-cash interest expense has grown at a -32.6% compound annual growth rate (CAGR), from $9.14M to $1.89M.